Table 3 Prevalence of disease presentation according to the onset of Raynaud's phenomenon.
| DcSSc | p (early vs late) | lcSSc | p (early vs late) | |||
|---|---|---|---|---|---|---|
| Early Raynaud | Late Raynaud | Early Raynaud | Late Raynaud | |||
| Number of patients | 553 | 594 | NA | 914 | 1003 | NA |
| Age (years), mean (SD) | 42.8 (11.9) | 60.9 (8.5) | <0.001 | 49.9 (12.9) | 64.1 (8.6) | <0.001 |
| Women | 84.6% | 77.9% | 0.004 | 93.1% | 89.4% | 0.004 |
| ANA positive | 93.8% | 93.4% | 0.76 | 92.5% | 91.6% | 0.46 |
| Scl70 positive | 63.2% | 60.0% | 0.26 | 25.5% | 21.5% | 0.04 |
| ACA positive | 5.5% | 6.6% | 0.45 | 46.5% | 49.6% | 0.18 |
| mRSS (years), mean (SD) | 18.7 (9.4) | 19.5 (10.4) | 0.18 | 8.1 (5.2) | 8.0 (5.2) | 0.66 |
| Active disease | 43.8% | 52.7% | 0.005 | 18.1% | 21.9% | 0.05 |
| Elevated acute‐phase reactants | 37.3% | 44.3% | 0.02 | 21.8% | 26.3% | 0.03 |
| Digital ulcers | 50.8% | 35.2% | <0.001 | 38.8% | 27.9% | <0.001 |
| Muscle weakness | 32.7% | 39.2% | 0.02 | 21.0% | 22.5% | 0.43 |
| Pulmonary fibrosis | 47.4% | 59.4% | <0.001 | 31.8% | 37.2% | 0.02 |
| Lung restrictive defect | 47.9% | 50.3% | 0.26 | 24.1% | 29.2% | 0.009 |
| PAH | 17.7% | 26.3% | <0.001 | 16.8% | 23.4% | <0.001 |
| Dyspnoea | 37.8% | 52.2% | <0.001 | 31.3% | 37.0% | 0.008 |
| Palpitations | 23.5% | 30.3% | 0.006 | 20.6% | 23.6% | 0.07 |
| Conduction block | 11.4% | 13.5% | 0.18 | 9.0% | 12.2% | 0.01 |
| Diastolic dysfunction | 11.9% | 20.7% | <0.001 | 12.2% | 18.6% | <0.001 |
| Hypertension | 11.6% | 23.9% | <0.001 | 12.9% | 22.0% | <0.001 |
ACA, anticentromere autoantibody; ANA, antinuclear antibodies; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; mRSS, modified Rodnan Skin Score; NA, not applicable; PAH, pulmonary artery hypertension (assessed by echocardiography).
Manifestations with statistically similar prevalence between early and late onset are not shown.